SY-201
/ Seinda Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
July 23, 2026
Efficacy and Safety of Closed-Loop Insulin Infusion Systems in Pediatric Patients with New-Onset Type 1 Diabetes Mellitus
(ChiCTR)
- P=N/A | N=84 | Recruiting | Sponsor: Children's Hospital of Fudan University; Children's Hospital of Fudan University
Head-to-Head • New trial • Diabetes • Metabolic Disorders • Pediatrics • Type 1 Diabetes Mellitus
March 26, 2025
A Phase 2, Double-Masked, Randomized, Vehicle-controlled Trial of SY201 in Dry Eye Disease in US
(ARVO 2025)
- "What they really want are treatments that work faster and more effectively—ones that not only help their eyes feel better but also improve their vision. In its Phase 2 study, SY201 eye drops showed rapid and significant improvement in dry eye symptoms and overall eye surface health by repairing the eye surface and restoring its natural balance."
Clinical • P2 data • Dry Eye Disease • Ophthalmology • MMP9
October 20, 2024
SY201. Video Laryngoscopy, Exploring Patient Safety and Costs(non-CME)
(ASA 2024)
- "Adam Thaler will discuss evaluating VL products for cost-effectiveness and implementation in his practice. Medtronic, Corporate Supporter"
Clinical • Video • Anesthesia
November 22, 2023
Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease
(clinicaltrials.gov)
- P1/2 | N=201 | Completed | Sponsor: Seinda Pharmaceutical Guangzhou Corporation | Recruiting ➔ Completed | Trial completion date: Jul 2023 ➔ Mar 2023 | Trial primary completion date: Jul 2023 ➔ Mar 2023
Trial completion • Trial completion date • Trial primary completion date • Dry Eye Disease • Ophthalmology
August 01, 2022
Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease
(clinicaltrials.gov)
- P1/2 | N=200 | Recruiting | Sponsor: Seinda Pharmaceutical Guangzhou Corporation | Not yet recruiting ➔ Recruiting
Enrollment open • Dry Eye Disease • Ophthalmology
May 11, 2022
Double-masked Controlled Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease
(clinicaltrials.gov)
- P1/2 | N=200 | Not yet recruiting | Sponsor: Seinda Pharmaceutical Guangzhou Corporation
New P1/2 trial • Dry Eye Disease • Ophthalmology
1 to 6
Of
6
Go to page
1